Iwilfin
Payments companies reported to CMS as associated with Iwilfin. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Iwilfin, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Iwilfin
These are the largest totals companies reported as associated with Iwilfin. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Giselle Saulnier- Sholler | Hershey, PA | Pediatric Hematology-Oncology | $179,602.04 |
| Scott Moerdler | New Brunswick, NJ | Pediatric Hematology-Oncology | $10,529.67 |
| Raya Saab | Palo Alto, CA | Pediatric Hematology-Oncology | $10,050.63 |
| Stacey Zahler | Cleveland, OH | Pediatric Hematology-Oncology | $9,622.86 |
| Mary Granger | Memphis, TN | Pediatric Hematology-Oncology | $8,217.77 |
| Aaron Sugalski | San Antonio, TX | Pediatric Hematology-Oncology | $8,149.99 |
| Jacqueline Kraveka | Charleston, SC | Pediatric Hematology-Oncology | $7,261.19 |
| Michael Hogarty | Philadelphia, PA | Pediatric Hematology-Oncology | $4,000.00 |
| Susan Cohn | Chicago, IL | Infectious Disease | $4,000.00 |
| William Ferguson | Saint Louis, MO | Pediatric Hematology-Oncology | $3,247.10 |
Prescribed Iwilfin?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.